Tivdak
Payments companies reported to CMS as associated with Tivdak. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tivdak, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tivdak
These are the largest totals companies reported as associated with Tivdak. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Thomas Krivak | Pittsburgh, PA | Gynecologic Oncology | $170,587.57 |
| Scott Jordan | Fort Lauderdale, FL | Obstetrics & Gynecology | $165,130.46 |
| Bradley Monk | West Palm Beach, FL | Gynecologic Oncology | $144,556.60 |
| Chirag Shah | Seattle, WA | Gynecologic Oncology | $132,856.57 |
| Joshua Kesterson | Newport, PA | Gynecologic Oncology | $130,270.75 |
| John Chan | San Francisco, CA | Gynecologic Oncology | $119,625.97 |
| Tiffany Redfern | Fort Worth, TX | Gynecologic Oncology | $113,882.47 |
| Shannon Fitzgerald | Allison Park, PA | Family | $98,840.64 |
| Heidi Godoy | Albany, NY | Gynecologic Oncology | $96,760.49 |
| Robert Morris | Detroit, MI | Gynecologic Oncology | $87,919.45 |
Prescribed Tivdak?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.